两个地区新生血管性年龄相关性黄斑变性十年治疗结局
该回顾性比较干预病例系列分析了澳大利亚与新西兰(ANZ)及瑞士在常规临床实践中自2006年1月1日至2008年12月31日启动抗VEGF治疗的712只新生血管性年龄相关性黄斑变性(nAMD)初治眼,比较完成10年治疗眼的视力变化。ANZ完成10年治疗的132只眼(28%)平均视力较基线下降0.9个字母(95%CI -4.9至3.1;P=0.7),瑞士完成10年治疗的37只眼(12%)下降14.9个字母(95%CI -24至-5.7;P<0.001)。作者结论认为nAMD眼接受充分治疗可能获得满意长期视力结局,ANZ视力结局较好可能因其接受更多注射。
要点
- ANZ完成10年治疗的132只眼(28%)平均视力较基线下降0.9个字母(95%CI -4.9至3.1;P=0.7)。
- 瑞士完成10年治疗的37只眼(12%)平均视力下降14.9个字母(95%CI -24至-5.7;P<0.001)。
- ANZ眼10年内注射中位数53次 vs 瑞士42次,ANZ就诊时活动性疾病比例38% vs 瑞士69%。
核心结论
- nAMD眼若接受充分治疗可能获得满意的长期视力结局。
- 接受长期VEGF抑制剂治疗的眼并非普遍发生黄斑中心萎缩,与既往担忧不同。
- ANZ患者眼视力结局较好,可能因其接受了更多注射。
研究设计与样本
- 回顾性、比较性、干预性病例系列。
- 分析712只初治眼(ANZ n=474;瑞士 n=321),于2006年1月1日至2008年12月31日在常规临床实践中启动抗VEGF治疗。
- 数据来自前瞻性设计的观察性数据库Fight Retinal Blindness!登记系统。
- 主要结局为完成10年治疗眼的视力(logMAR字母)平均变化。
主要发现
- ANZ完成10年治疗的132只眼(28%)平均视力较基线下降0.9个字母(95%CI -4.9至3.1;P=0.7),42%达到≥20/40。
- 瑞士完成10年治疗的37只眼(12%)平均视力下降14.9个字母(95%CI -24至-5.7;P<0.001),35%达到≥20/40。
- ANZ眼10年内注射中位数53次 vs 瑞士42次,ANZ眼就诊次数更少且疾病控制更好(活动性疾病就诊比例38% vs 69%)。
- 上述模式提示ANZ采用治疗-延长方案 vs 瑞士采用按需治疗(pro re nata,仅在病灶活动时给药)方案。
- 回顾性分析子集中,黄斑萎缩和视网膜下纤维化为视力下降10个字母的主要原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report and compare 10-year treatment outcomes of vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) from Australia and New Zealand (ANZ) and Switzerland. DESIGN: Retrospective, comparative, interventional case series. METHODS: We analyzed 712 treatment-naive eyes (ANZ, n = 474; Switzerland, n = 321) starting anti-VEGF for nAMD in routine clinical practice between January 1, 2006, and December 31, 2008, tracked in the prospectively designed observational database, the Fight Retinal Blindness! registry. The primary outcome was mean change in visual acuity (VA [in logMAR letters]) in eyes that completed 10 years of treatment. RESULTS: The mean VA in 132 eyes (28%) from ANZ patients who completed 10 years of treatment dropped by 0.9 letters from baseline (95% confidence interval [CI], -4.9 to 3.1; P = 0.7) with 42% achieving ≥20/40, whereas the 37 eyes (12%) from Swiss subjects lost 14.9 letters (95% CI, -24 to -5.7; P < 0.001) with 35% achieving ≥20/40. Eyes from ANZ patients received more injections than eyes from Swiss subjects over 10 years (a median of 53 vs 42, respectively) from fewer visits with better disease control (proportion of visits with active disease: 38% vs 69%, respectively), suggesting a treat-and-extend regimen versus a pro re nata regimen (treatment given only when the lesion is active). Macular atrophy and subretinal fibrosis were the main reasons for 10 letter loss in the subset of eyes analyzed retrospectively. The mean VA of eyes from both regions that discontinued treatment within 10 years had fallen below the baseline at their final visit. CONCLUSIONS: Eyes with nAMD may achieve satisfactory long-term visual outcomes if they receive adequate treatment. Central macular atrophy does not develop universally in eyes receiving long-term treatment with VEGF inhibitors as previously feared. Visual outcomes were better in eyes from ANZ patients, likely because they received more injections.
引用
- Gillies M, Arnold J, Bhandari S, et al. Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. Am J Ophthalmol. 2019. PMID: 31606444. doi:10.1016/j.ajo.2019.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。